)
)
)
Model Medicines
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Infectious Diseases
Model Medicines is an AI-native biotechnology company developing first-in-class small-molecule therapeutics by targeting conserved biological choke points that drive disease across multiple indications. Its proprietary discovery platform integrates multimodal AI, generative chemistry, and predictive safety modeling to enable end-to-end drug discovery, from novel target identification through preclinical proof-of-concept. The lead program, MDL-001, is the first oral, direct-acting, non-nucleoside antiviral targeting a previously undiscovered allosteric site in viral RNA-dependent RNA polymerase (RdRp Thumb-1). MDL-001 has demonstrated broad-spectrum preclinical efficacy across respiratory and liver viruses, including SARS-CoV-2, influenza, RSV, HCV, HBV, and HDV, and is advancing toward IND submission in late 2026. MDL-001 was presented at IDWeek, The Liver Meeting® (AASLD), and HepDART. Model Medicines was recently named a Fierce 15 company and selected for BARDA’s VANGUARD program.
Year Founded:
2019
Lead Product in Development:
MDL-001 – A first-in-class, oral, direct-acting, broad-spectrum antiviral targeting the conserved RdRp Thumb-1 allosteric site. MDL-001 has demonstrated preclinical efficacy across respiratory and liver viruses, including SARS-CoV-2, influenza, RSV, HCV, HBV, and HDV, and is advancing toward IND submission in late 2026.
MDL-4102 – A first-in-class, highly selective small-molecule BRD4 inhibitor designed to overcome the dose-limiting toxicities associated with prior BET inhibitors. Discovered through record-scale AI-driven virtual screening, MDL-4102 is advancing through preclinical development toward IND submission in early 2027.
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
